

Twinsight Closes €1.6 Million Seed Round to Accelerate US Commercialization of FDA-cleared SurgiTwin™ 3D and Complete Development Work on SurgiTwin™ 4D.

The Grenoble-based medtech company reached its €1.6 million seed target, with the equity portion raised solely from individual investors. The round was marked by renewed support from existing backers, including Grenoble Angels, and the company's first international investors. The influx of capital comes with additional non-dilutive bank financing. The company also welcomed two new board members as it prepares to enter the US market in 2026.

GRENOBLE, France – July 17, 2026 – Twinsight, a French medical technology company specializing in orthopedic surgical planning software, today announced the completion of its seed fundraising round, raising a total of €1.6 million. The round marks a decisive step for Twinsight, positioning the company to build on its recent FDA 510(k) clearance for SurgiTwin™ 3D and establish a strong commercial foothold in the United States while finalizing the development of SurgiTwin™ 4D and securing FDA clearance for the new solution.

Renewed commitment from existing investors and a demonstration of trust from surgeons

The €1.6 million raised combines equity financing with non-dilutive bank loans, secured with the support of Bpifrance, Caisse d'Epargne, and Crédit Agricole Sud Rhône Alpes.

Notably, the equity portion of the round was raised exclusively from individual investors who believe in Twinsight's vision. The support of individual angel investors, including expert orthopedic surgeons, sends a strong signal that SurgiTwin™ 3D addresses a genuine, unmet need in the field. The round also marks a milestone for Twinsight's international growth strategy, with the arrival of US investors and LBAN (Luxembourg Business Angel Network), who have now joined Grenoble's angel investors, *Grenoble Angels*, with Twinsight from the beginning.

"We are proud to count these expert surgeons among our investors," said Twinsight CEO Mathieu Rimaud. "Their support, alongside the continued trust of our individual investors, sends a strong signal that SurgiTwin™ 3D already responds to a real market need. This funding is decisive for Twinsight: It will allow us to fully capitalize on our FDA clearance and take our technology to surgeons across the United States. 2026 will be the year we officially enter the US market. The funds raised will also support continued development towards clearance of the next version of our software: SurgiTwin™ 4D, which will bring our innovative biomechanical digital twin concept to the next level."

"We are delighted to continue supporting Twinsight, a pioneering Grenoble-based medtech company as it advances medical research with its AI-enabled software solution, SurgiTwin™ 3D. It is particularly exciting to see the remarkable progress the team has made in addressing the U.S market. We are also proud to participate in this cross-border European financing round alongside LBAN – the Luxembourg Business Angel Network – also a member of the European Business Angels Network (EBAN). This investment reflects the value of cross-border collaboration in helping innovative European deeptech companies scale internationally," said Philippe Rase, President, Grenoble Angels and Co-President, France Angels.

Strengthening governance for the next stage of growth

In addition to the successful completion of this seed round, Twinsight also announced the appointment of two new members to its Board of Directors: Cyrille Fleury and David Anderson.

A recognized leader in the medical device industry, Cyrille Fleury brings more than twenty years of operational and strategic leadership experience. As former CEO of Groupe Menix, he drove strong growth, launched AI-driven innovations, and led international expansion—including the opening of a US subsidiary—culminating in the successful sale of SERF to Stryker. He also held senior leadership roles at Tornier and Wright Medical. Cyrille currently is the Chairman of Galmeon and sits on the boards of several healthcare companies and on the board of directors of SNITEM, the French national federation of medical technology industries.

A global marketing and business development executive in the medical device and biologics industry, David Anderson brings a consistent track record of growing revenues through the application of marketing fundamentals and effective leadership. He is recognized for strategic thinking from organization to product, and for creating value through M&As. "I'm honored to join the Twinsight Board of Directors," said Anderson. "Twinsight's digital twin technology has the potential to transform total knee replacement planning by enabling more personalized implant placement while enhancing surgical efficiency. The combination of clinical impact, technological innovation, and market opportunity makes this an exciting time to be part of the company's journey."

Looking ahead to 2026

Building on its FDA 510(k) clearance obtained for SurgiTwin™ 3D in 2025, the influx of capital and the strategic insights of the two new board members will position Twinsight to build its network of experts and partners in the US to prepare for commercial ramp-up and boost revenue growth as SurgiTwin™ 3D reaches surgeons across the United States. The funds raised will also allow Twinsight to finalize development of SurgiTwin™ 4D and begin the FDA 510(k) clearance process—a decisive step toward broadening Twinsight's solutions for the US market.

About Twinsight

Founded in 2020 and based in La Tronche (Grenoble), France, Twinsight is a medical technology company dedicated to developing innovative software solutions for orthopedic surgery planning. The company's mission is to provide surgeons with a dynamic digital twin of each patient to personalize and improve surgical care. Today, the company's groundbreaking SurgiTwin™ 3D is bringing unprecedented levels of precision to knee replacement surgery while saving precious operating room time. In the future, Twinsight intends to bring the power of personalized digital twins to joints other than the knee and introduce dynamic movement into its models to provide unprecedented 4D simulation. The company's solutions will make operating blind a thing of the past by giving surgeons actionable data designed to improve patient outcomes.

Twinsight's multidisciplinary team combines expertise in medical imaging, artificial intelligence, orthopedic surgery, and regulatory affairs to develop advanced technological solutions that address real-world clinical challenges.

Contact Information

Mathieu Rimaud

mathieu.rimaud@twinsight-medical.com

+33668020561